FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD
The U.S. Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and […]
Devices for hyperhidrosis: A review of old and new options
Michael Gold, MD, with Bob Kronemyer Despite having at our disposal highly effective old and new medications to treat hyperhidrosis, ranging from topical aluminum chloride hexahydrate (Drysol, Person & Covey, Inc.) to the glycopyrronium cloth (Qbrexza, Dermira), medical devices still have a place. However, there is currently only one FDA-cleared device for axillary hyperhidrosis: miraDry […]
Literature lessons
Research updates in COVID-19, pediatric dermatology, infectious diseases, atopic dermatitis, cutaneous oncology, and more By Ted Rosen, MD, FAAD, Editor-in-Chief Off-label pearl Pentoxifylline for treatment of claudication Pentoxifylline is an oral xanthine derivative FDA-approved for the treatment of claudication. Pentoxifylline increases deformability of red blood cells, decreasing blood viscosity and enhancing tissue oxygenation. As a […]